演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

再発子宮頸癌に対してベバシズマブを使用した症例の臨床的検討

演題番号 : P94-7

[筆頭演者]
演者)香坂 信明:1 
[共同演者]
長谷川 清志:1、木内 香織:1、坂本 尚徳:1、深澤 一雄:1

1:獨協医科大学・産婦人科

 

[Purpose] The prognosis of recurrent or metastatic cervical cancers is generally poor. Gynecologic Oncology Group (GOG) 240 study with bevacizumab (Bev) containing chemotherapy demonstrated a significant improvement of disease free survival and overall survival in metastatic, persistent, and recurrent cervical cancer. We, herein, evaluated Bev containing chemotherapy for the patients with recurrent cervical cancer.
[Methods] The efficacy and adverse effects of Bev containing chemotherapy for 7 patients with recurrent cervical cancers were investigated.
[Results] The median age was 67 years (range, 38 to 74 years). The initial FIGO stage was as follows; 2 patients with IB1, 3 with IB2, IIIA, and IIIB, respectively, and 2 with IVB. As the histological type, 4 patients were with squamous cell carcinoma, 2 with adenocarcinoma, and 1 with adenosquamous carcinoma. As recurrent site, 3 patient were of lymph nodes, 2 of lung, 1 of vaginal stump, 1 of lumbar spine. Six patients underwent radiotherapy and platinum-based chemotherapy, and 1 patients underwent adjuvant chemotherapy alone for initial treatment or postoperative adjuvant setting. Six patients received weekly paclitaxel with Bev, and one received paclitaxel/carboplatin with Bev. The clinical response was 1 patient of complete response (CR), 2 of partial response (PR), 3 of stable disease (SD), and 1 of progressive disease. The overall response rate was 42.9%, and the disease control rate (CR+PR+SD) was 85.8%. The median progression-free survival was 4 months (range; 2 to 10 months). Major adverse effects were hypertension (2 patients), proteinuria (1 patient), and bladder dysfunction after ischemic/ hemorrhagic cystitis (1 patients).
[Conclusion] Bev containing chemotherapy is effective for recurrent cervical cancer. However, it may be required careful selection of the patients for Bev treatment. The clinicians should be aware of the urinary tract disorders as well GI fistula.

キーワード

臓器別:子宮

手法別:分子標的治療

前へ戻る